Safety and efficacy of laser trabeculoplasty compared to drug therapy for the management of open-angle glaucoma: systematic review and meta-analysis study.
Zhang Yangzhou, Yang Huiling, Pu Jipu, Guo Yan
AI Summary
This meta-analysis found laser trabeculoplasty and drug therapy similarly effective for OAG IOP control. LT reduces medication need and is a safe, viable first-line option, especially selective LT.
Abstract
Background
Intraocular pressure (IOP) reduction is the approach that is commonly accepted for the control of open-angle glaucoma (OAG). Medical therapy is typically the first-line of treatment. Laser trabeculoplasty (LT) is an alternative therapy; however, whether pharmaco-therapeutic options can be replaced by LT as the first-line is still debatable.
Methods
studies conducted till July 2023 that compared the efficacy of medications and LT for OAG were retrieved from databases such as Embase, PubMed, Cochrane Library, and Web of Science. We completed data extraction for outcomes of interest. The quality of eligible studies was evaluated and random-effects (RE) model was applied for analysis.
Results
A total of eighteen trials with 2024 patients were included in the analysis. Overall, there was no statistically significant difference between therapies including laser trabeculoplasty (LT) and drug therapy in terms of successful IOP control (RR:1.30, 95%CI: 0.96, 1.78, P = 0.09, I 2 = 96%), and reducing intraocular pressure (IOP) (MD:0.15; 95%CI:-0.55,0.85; P = 0.67, I 2 = 62%). A significant reduction in drug therapy need in comparison to the group that received medicine (MD:-1.07; 95%CI;-1.21,-0.93), P < 0.001, with a low heterogeneity level (I 2 = 16%). Adverse ocular events were more common in the argon laser group (RR:11.71, 95%CI: 9.93, 23.1; P < 0.001).
Conclusion
Both LT and topical drug therapy exhibit comparable rates of success and efficacy in reducing intraocular pressure in patients with open-angle glaucoma. Selective LT is considered a safe treatment option with a reduced occurrence of adverse effects on the eyes while eliminating the possible adherence concerns associated with topical medicine and it can be considered a viable initial option for first OAG treatment.
Key messages: What is known Drug therapy is typically the 1st line of treatment for open-angle glaucoma. Although drugs have been shown to effectively reduce intraocular pressure (IOP), they are associated with a range of ocular and systemic negative effects which contributes to suboptimal adherence to medications. Laser trabeculoplasty (LT) is an alternative therapy; however, whether pharmaco-therapeutic options can be replaced by LT as the first-line is still debatable. What is new In terms of IOP reduction and IOP success rate, LT therapy was comparable in efficacy to drug therapy according to our findings. The safety profile of selective LT was found to be preferable compared to Argon LT.
MeSH Terms
Shields Classification
Key Concepts6
There was no statistically significant difference between laser trabeculoplasty (LT) and drug therapy in terms of successful intraocular pressure (IOP) control (RR: 1.30, 95%CI: 0.96, 1.78, P = 0.09, I2 = 96%) in patients with open-angle glaucoma.
There was no statistically significant difference between laser trabeculoplasty (LT) and drug therapy in reducing intraocular pressure (IOP) (MD: 0.15; 95%CI: -0.55, 0.85; P = 0.67, I2 = 62%) in patients with open-angle glaucoma.
A significant reduction in drug therapy need was observed in the laser trabeculoplasty (LT) group compared to the group that received medicine (MD: -1.07; 95%CI: -1.21, -0.93), P < 0.001, with a low heterogeneity level (I2 = 16%) in patients with open-angle glaucoma.
Adverse ocular events were more common in the argon laser group (RR: 11.71, 95%CI: 9.93, 23.1; P < 0.001) compared to other therapies for open-angle glaucoma.
Both laser trabeculoplasty (LT) and topical drug therapy exhibit comparable rates of success and efficacy in reducing intraocular pressure in patients with open-angle glaucoma.
Selective laser trabeculoplasty (SLT) is considered a safe treatment option with a reduced occurrence of adverse effects on the eyes while eliminating possible adherence concerns associated with topical medicine and can be considered a viable initial option for first open-angle glaucoma (OAG) treatment.
Related Articles5
The impact of topical NSAID treatment on selective laser trabeculoplasty efficacy.
Observational StudySelective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials.
Systematic ReviewThe Glaucoma Laser Trial (GLT). 2. Results of argon laser trabeculoplasty versus topical medicines. The Glaucoma Laser Trial Research Group.
Randomized Controlled TrialApraclonidine and argon laser trabeculoplasty.
Randomized Controlled TrialFive-year follow up of selective laser trabeculoplasty in Chinese eyes.
Randomized Controlled TrialIs this article assigned to the wrong chapter(s)? Let us know.